Fig. 7

Impact of TLR2 and TLR9 inhibitors on microglial phagocytic capacity of β-amyloid in vitro. A Left: level of mRNA expression of MSR1 in microglial cells stimulated with MOI = 20 of K. variicola or Lipoteichoic acid (LTA)–TLR2 agonist at a concentration of 10 µg/mL for 24 h, with or without the addition of TLR2 antagonistic antibody T2.5 at a concentration of 10 µg/mL for 1 h before the K. variicola or LTA stimulation. Right: level of mRNA expression of MSR1 in microglial cells stimulated with MOI = 20 of K. variicola or CpG oligonucleotides (ODN1826)–TLR9 ligand at a concentration of 1 µM for 24 h, with or without the addition of TLR9 antagonist (ODN2088) at a concentration of 1 µM for 1 h before the K. variicola or ODN1826 stimulation (Mean ± SEM, ANOVA, ***p < 0.001, ****p < 0.0001). B Percentage of β-Amyloid 488 Fluor⁺ microglial cells stimulated with MOI = 20 of K. variicola for 24 h with or without the addition of TLR2 antagonistic antibody T2.5 and TLR9 antagonist (ODN2088) either alone or in combination for 1 h before the K. variicola stimulation. (a representative experiment in triplicate from three different experiments, mean ± SEM, ANOVA, **p < 0.01, ****p < 0.0001)